Ocumension Therapeutics 1477

HKEX · Hong Kong SAR China · Commercial Services

HKD 5.10+0.01 (+0.29%)

Market closed· Oct 2, 2026, 8:08 AM UTC· HKD · Data may be delayed

Company news

Yahoo FinanceJul 01, 2026

Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment

Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) by exclusive licensee Kowa Company, Ltd. (Kowa) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension€3 million milestone payment due to Nicox, with a further milestone payment due upon approvalSubmission based on posit

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.